Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Treasury Shares (2017 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Treasury Shares for 4 consecutive years, with $44.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 2077.97% to $14.9 million in Q4 2025 year-over-year; TTM through Oct 2025 was $14.9 million, a 2077.97% increase, with the full-year FY2025 number at $14.9 million, up 9.11% from a year prior.
  • Treasury Shares was $14.9 million for Q4 2025 at PharmaCyte Biotech, roughly flat from $14.9 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $14.9 million in Q2 2025 to a low of -$13.2 million in Q1 2024.
  • A 4-year average of $32.8 million and a median of $41.4 million in 2024 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: skyrocketed 1813.96% in 2023, then rose 0.91% in 2025.
  • PharmaCyte Biotech's Treasury Shares stood at $900.0 in 2021, then soared by 230470.44% to $2.1 million in 2022, then crashed by 725.12% to -$13.0 million in 2023, then skyrocketed by 105.27% to $683036.0 in 2024, then surged by 2077.97% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Treasury Shares are $14.9 million (Q4 2025), $14.9 million (Q3 2025), and $14.9 million (Q2 2025).